We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

52 hedge funds and large institutions have $113M invested in Avalo Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

5% less funds holding

Funds holding: 55 → 52 (-3)

11% less capital invested

Capital invested by funds: $127M → $113M (-$13.9M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
52
Holders Change
-3
Holders Change %
-5.45%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
22
Reduced
14
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.87M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.03M
3
Two Sigma Investments
Two Sigma Investments
New York
+$864K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$699K
5
BlackRock
BlackRock
New York
+$646K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$1.17M
2
DCM
DAFNA Capital Management
California
-$827K
3
Renaissance Technologies
Renaissance Technologies
New York
-$744K
4
IC
Ikarian Capital
Texas
-$526K
5
Millennium Management
Millennium Management
New York
-$368K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$58K -$22.5K -3 -25%
JP Morgan Chase
27
JP Morgan Chase
New York
$57K – – –
TS
28
Tamar Securities
California
$53K – – –
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$49K -$7.52K -1 -13%
AIG
30
American International Group
New York
$49K +$15K +2 +33%
Deutsche Bank
31
Deutsche Bank
Germany
$44K +$15K +2 +40%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$42K +$7.52K +1 +20%
AllianceBernstein
33
AllianceBernstein
Tennessee
$41K -$15K -2 -25%
Barclays
34
Barclays
United Kingdom
$37K – – –
Citadel Advisors
35
Citadel Advisors
Florida
$32K -$15K -2 -29%
SIM
36
Spark Investment Management
New York
$28K – – –
CSS
37
Cubist Systematic Strategies
Connecticut
$26K -$52.6K -7 -64%
Victory Capital Management
38
Victory Capital Management
Texas
$26K – – –
PNC Financial Services Group
39
PNC Financial Services Group
Pennsylvania
$23K +$22.5K +3 New
Prudential Financial
40
Prudential Financial
New Jersey
$23K +$30.1K +4 New
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$21.1K +$15K +2 +200%
Legal & General Group
42
Legal & General Group
United Kingdom
$11K – – –
MAM
43
Meeder Asset Management
Ohio
$10K – – –
UBS Group
44
UBS Group
Switzerland
$8K -$30.1K -4 -80%
Bank of America
45
Bank of America
North Carolina
$8K -$15K -2 -67%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$8K – – –
Morgan Stanley
47
Morgan Stanley
New York
$7K -$15K -2 -67%
TWA
48
TCI Wealth Advisors
Arizona
$7K – – –
AIP
49
Ameritas Investment Partners
Nebraska
$4K – – –
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$4K – – –
1
2
3

AVTX Hedge Fund Activity: Q3 2020 in Review

52 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2020, worth a combined $113M — down 11% from $127M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of AVTX and 2 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 22 added.

The largest buyer was Vanguard Group, adding an estimated $1.87M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.17M sold.

  • 52 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2020, down from 55 in Q2 2020.
  • Funds reported $113M of Avalo Therapeutics stock for Q3 2020, down 11% quarter-over-quarter.
  • 2 funds opened new Avalo Therapeutics positions in Q3 2020 and 5 closed out, a net change of -3 holders.
  • The largest Avalo Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $1.87M added.
  • The largest Avalo Therapeutics seller in Q3 2020 was Stonepine Capital Management, an estimated $1.17M sold.

Based on aggregated 13F filings for Q3 2020.